Venus Unit Signs With Mylan To Market Antibiotic In Europe
This article was originally published in PharmAsia News
Executive Summary
The Germany unit of Venus Remedies and Mylan have signed an agreement that would have the India-based company license its Meropenem antibiotic in three European countries for five years.